Comorbidities significantly complicate multiple sclerosis management by exacerbating symptoms and influencing clinical decision-making.
This qualitative pilot study found that comorbidities add significant complexity to MS management, as reported by both individuals with MS and healthcare professionals. The study identified a need for enhanced coordination and interdisciplinary care models, and highlighted research gaps on comorbidities like insomnia and substance use.
Evidence Score
Study Evidence
Study 1. Bridging perspectives on comorbidities in multiple sclerosis: A pilot study with individuals with lived experience and healthcare professionals.
observationalKarim ME, Sage O, Thandi M, Frank HA, Marrie RA, Tremlett H, McKay K, Cox S, Lix L, Zhu F, Yusuf F ยท Multiple sclerosis and related disorders (2026)
Result:
Mechanism Graph
Limitations
- โ Small sample size (n=10 total)
- โ Qualitative design limits generalizability
Frequently Asked Questions
What comorbidities were specifically mentioned in the study?โผ
The study specifically highlighted insomnia and substance use as comorbidities with gaps in research on their effects on MS outcomes.
How many participants were in this study?โผ
The study included 10 participants: 5 individuals living with MS and 5 healthcare professionals.
What type of study design was used?โผ
This was a qualitative pilot study using semi-structured interviews and thematic analysis.
What was the main recommendation from the study?โผ
The study recommended integrated care models, enhanced communication between specialists, and further research on links between MS and comorbidities.
Products
Affiliate links coming soon. We only recommend products that match the doses and forms used in the cited research.
References
- 1.Karim ME, Sage O, Thandi M, Frank HA, Marrie RA, Tremlett H, McKay K, Cox S, Lix L, Zhu F, Yusuf F. "Bridging perspectives on comorbidities in multiple sclerosis: A pilot study with individuals with lived experience and healthcare professionals.." Multiple sclerosis and related disorders, 2026. PMID: 41830893 DOI: 10.1016/j.msard.2026.107127